{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:57:08Z","timestamp":1792691828366,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T00:00:00Z","timestamp":1628726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.xphs.2021.08.012","type":"journal-article","created":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T18:11:43Z","timestamp":1628878303000},"page":"3946-3952","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["Improved Bioavailability with Dry Powder Cannabidiol Inhalation: A Phase 1 Clinical Study"],"prefix":"10.1016","volume":"110","author":[{"given":"Orrin","family":"Devinsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8225-907X","authenticated-orcid":false,"given":"Kelly","family":"Kraft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine","family":"Rusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Fein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Leone-Bay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.xphs.2021.08.012_bib0001","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/epi.12631","article-title":"Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders","volume":"55","author":"Devinsky","year":"2014","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.xphs.2021.08.012_bib0002","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD009270.pub2","article-title":"Cannabinoids for epilepsy","author":"Gloss","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.xphs.2021.08.012_bib0003","unstructured":"Greenwich Biosciences. Epidiolex\u00ae (cannabidiol) oral solution [package insert]. U.S. Food and Drug Administration Website. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/210365s005s006s007lbl.pdf. Accessed February 18, 2021."},{"issue":"2","key":"10.1016\/j.xphs.2021.08.012_bib0004","doi-asserted-by":"crossref","first-page":"93","DOI":"10.31887\/DCNS.2017.19.2\/bbandelow","article-title":"Treatment of anxiety disorders","volume":"19","author":"Bandelow","year":"2017","journal-title":"Dialogues Clin Neurosci"},{"issue":"3","key":"10.1016\/j.xphs.2021.08.012_bib0005","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/bph.12944","article-title":"Are cannabidiol and \u0394(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review","volume":"172","author":"McPartland","year":"2015","journal-title":"Br J Pharmacol"},{"issue":"8","key":"10.1016\/j.xphs.2021.08.012_bib0006","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1111\/j.1476-5381.2011.01621.x","article-title":"Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus","volume":"165","author":"Rock","year":"2012","journal-title":"Br J Pharmacol"},{"issue":"4","key":"10.1016\/j.xphs.2021.08.012_bib0007","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s13311-015-0387-1","article-title":"Cannabidiol as a potential treatment for anxiety disorders","volume":"12","author":"Blessing","year":"2015","journal-title":"Neurotherapeutics"},{"issue":"2","key":"10.1016\/j.xphs.2021.08.012_bib0008","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2174\/1570159X14666160509123955","article-title":"Evidences for the anti-panic actions of cannabidiol","volume":"15","author":"Soares","year":"2017","journal-title":"Curr Neuropharmacol"},{"issue":"6","key":"10.1016\/j.xphs.2021.08.012_bib0009","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/npp.2011.6","article-title":"Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-na\u00efve social phobia patients","volume":"36","author":"Bergamaschi","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.xphs.2021.08.012_bib0010","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00213-012-2955-y","article-title":"Cannabidiol enhances consolidation of explicit fear extinction in humans","volume":"226","author":"Das","year":"2013","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.xphs.2021.08.012_bib0011","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1590\/1516-4446-2017-0015","article-title":"Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test","volume":"41","author":"Linares","year":"2019","journal-title":"Braz J Psychiatry"},{"issue":"1 Suppl","key":"10.1016\/j.xphs.2021.08.012_bib0012","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1177\/026988119300700112","article-title":"Effects of ipsapirone and cannabidiol on human experimental anxiety","volume":"7","author":"Zuardi","year":"1993","journal-title":"J Psychopharmacol"},{"issue":"11","key":"10.1016\/j.xphs.2021.08.012_bib0013","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s40263-018-0578-5","article-title":"A phase i, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects","volume":"32","author":"Taylor","year":"2018","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.xphs.2021.08.012_bib0014","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00406-019-00978-2","article-title":"A randomised controlled trial of vaporised Delta(9)-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects","volume":"269","author":"Solowij","year":"2019","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"107937","key":"10.1016\/j.xphs.2021.08.012_bib0015","doi-asserted-by":"crossref","first-page":"107937","DOI":"10.1016\/j.drugalcdep.2020.107937","article-title":"Pharmacodynamic effects of vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis in infrequent cannabis users","volume":"211","author":"Spindle","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.xphs.2021.08.012_bib0016","unstructured":"MannKind Corporation. Afrezza\u00ae (insulin human) inhalation powder [package insert]. U.S. Food and Drug Administration Website. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/022472lbl.pdf. Accessed February 16, 2021."},{"key":"10.1016\/j.xphs.2021.08.012_bib0017","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.3389\/fimmu.2018.02009","article-title":"Translational investigation of the therapeutic potential of Cannabidiol (CBD): toward a new age","volume":"9","author":"Crippa","year":"2018","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.xphs.2021.08.012_bib0018","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.3390\/biom10111575","article-title":"Cannabidiol: a potential new alternative for the treatment of anxiety, depression, and psychotic disorders","volume":"10","author":"Garcia-Gutierrez","year":"2020","journal-title":"Biomolecules"},{"issue":"21","key":"10.1016\/j.xphs.2021.08.012_bib0019","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Cannabidiol in Dravet Syndrome Study G 2017. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.xphs.2021.08.012_bib0020","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","article-title":"Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome","volume":"378","author":"Devinsky","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xphs.2021.08.012_bib0021","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/jamaneurol.2020.4607","article-title":"Add-on cannabidiol treatment for drug-resistant seizures in tuberous sclerosis complex: a placebo-controlled randomized clinical trial","volume":"78","author":"Thiele","year":"2021","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.xphs.2021.08.012_bib0022","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/phar.2377","article-title":"Model-based analysis of cannabidiol dose-exposure relationship and bioavailability","volume":"40","author":"Lim","year":"2020","journal-title":"Pharmacotherapy"},{"issue":"6","key":"10.1016\/j.xphs.2021.08.012_bib0023","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1046\/j.1365-2125.2003.01892.x","article-title":"Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications","volume":"56","author":"Labiris","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.xphs.2021.08.012_bib0024","article-title":"Government of Canada","author":"Abramovici","year":"2018","journal-title":"Information for healthcare professionals: Cannabis (marihuana, marijuana) and cannabinoids, Health Canada"},{"issue":"4","key":"10.1016\/j.xphs.2021.08.012_bib0025","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1080\/17425247.2016.1224846","article-title":"Dry powder inhalation: past, present and future","volume":"14","author":"de Boer","year":"2017","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"10.1016\/j.xphs.2021.08.012_bib0026","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1089\/can.2015.0012","article-title":"Human metabolites of cannabidiol: a review on their formation, biological activity, and relevance in therapy","volume":"1","author":"Ujvary","year":"2016","journal-title":"Cannabis Cannabinoid Res"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354921004135?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354921004135?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:35:15Z","timestamp":1758360915000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354921004135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0022354921004135"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2021.08.012","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improved Bioavailability with Dry Powder Cannabidiol Inhalation: A Phase 1 Clinical Study","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2021.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc. on behalf of American Pharmacists Association.","name":"copyright","label":"Copyright"}]}}